Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Amit Sanyal, MD: A Clinician’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jul
29
Today In Oncology
Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer
FDA Releases Final Guidances to Expand Participation in Cancer Clinical Trials
Phase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E-Positive Differentiated Thyroid Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo